For these patients with HF and an LVEF of 40% or more, ARNIs may be considered to replace ACE inhibitors or ARBs if tolerated, and SGLT2 inhibitors and MRAs may be recommended to be added when indicated. This evidence concerns the gene SLC5A2 and hydrops fetalis.